Therapeutic innovations in hemophilia: the essential role of a positive reinvestment cycle

Hemophilia stands out among rare genetic diseases for its significant therapeutic advancements, closely tied to substantial financial investments. Key factors driving this progress include severe hemorrhagic consequences from an early age, its impact on royal families, the HIV and hepatitis C contamination tragedies, the identification of factor VIII (FVIII) and FIX genes, and advancements in biotechnology. Maintaining low, measurable concentrations of FVIII or FIX in the blood has proven pivotal in improving patient outcomes. The mobilization of the global hemophilia community, led by the World Federation of Hemophilia, the European Association for Haemophilia and Allied Disorders, and the National Bleeding Disorder Foundation, has continuously advocated for access to safe, effective treatments. With reinvestments from biopharmaceutical partners, revolutionary options, including gene therapy, have emerged. However, this cycle of innovation and investment, essential for curing all patients worldwide, faces potential threats. This article aims to highlight the critical importance of investing in hemophilia treatment and research, a topic of concern for all stakeholders within the hemophilia community.